Furthermore, underlying reasons for the lower PCa rates observed may include factors such as reduced PSA screening, the suppressive effects of estrogen on PCa development, or the possibility of misdiagnosis due to misinterpretation of PSA levels in individuals undergoing gender-affirming hormone treatment [5]. The gene discussed is KLK3; the disease is posterior cortical atrophy.